Drug-Eluting Balloon Market Size (2025 – 2030)

The Drug-Eluting Balloon Market was valued at USD 0.79 billion in 2024 and is projected to reach a market size of USD 1.29 billion by the end of 2030. Over the forecast period of 2025-2030, the market is projected to grow at a CAGR of 8.48%.

The Drug-Eluting Balloon (DEB) Market refers to a fundamentally different segment of interventional cardiology, which deals with the use of advanced balloon catheters that are coated with drugs that inhibit cell growth to prevent the narrowing of the blood vessels after angioplasty procedures. These groundbreaking devices generate the very needed release of therapeutic agents to the arterial wall from where they diffuse, thus they minimize the rate of recurrence of blockages without the introduction of any permanent implants, as opposed to the traditional stents. In response to the above, the market shows incredible expansion, which is mainly caused by the three major factors, i.e., the growing rate of cardiovascular diseases, the increased demand for less invasive procedures, and the good clinical outcomes, which are attributed to the use of drug-eluting balloons in the treatment of complicated lesions and small vessels. Moreover, innovations in drug coatings, balloon materials, and delivery systems have, in turn, opened up the clinical use of these devices to both coronary and peripheral artery interventions. Thus, regions like North America and Europe are leading because of their stable healthcare infrastructure and easy-to-get regulatory approvals, while the Asia-Pacific region is becoming the fastest-growing market that is mainly driven by better healthcare access and increasing cardiovascular burden. With the ongoing clinical trials and increased physician adoption, the drug-eluting balloon market is gradually becoming the next big thing in interventional cardiology, thus giving patients safer and more efficient options for long-term vascular healing.

Key Market Insights:

Global burden studies show 113–114 million people with PAD (GBD/healthdata estimates for 2019–2021 era), and other sources estimate PAD case counts in the tens to hundreds of millions, driving increased peripheral angioplasty procedures where DEBs are used. Numeric note: the GBD-derived PAD case totals are ~113.7 million (recent GBD analyses).
Source: Global burden / GBD analyses.

Regional interventional cardiology data (ESC / country registries) show high PCI and peripheral procedure density growth in many APAC countries; clinical adoption and device uptake have accelerated as hospitals modernize and procedural capacity increases. Numeric note: interventional procedure density (PCI per million) varies widely by country, but high-income regions in Europe show 2,300 PCI/million as a benchmark. Asia shows rapidly rising per-million procedure rates in several markets (and large absolute patient pools). This combination supports faster unit adoption in APAC versus many mature markets.

Large-scale medtech surveys show widespread investment in digital/AI tools — two-thirds of medtech leaders report implementing GenAI pilots, and many are using data/AI to speed clinical evidence, regulatory packages, and post-market surveillance. Numeric note: a fall-2024 MedTech survey found roughly 66% of medtech execs reporting active GenAI implementation or pilots (early but meaningful adoption). Faster evidence generation and digital registries shorten conversion time from trial to adoption for novel DEB platforms. McKinsey & Company+1

Market Drivers:

Rising Burden of Cardiovascular Diseases and Peripheral Artery Disorders is Driving Drug-Eluting Balloon Market Growth.

The drug-eluting balloon market is largely influenced by the growing prevalence of cardiovascular diseases (CVDs) and peripheral artery disorders (PADs) globally. A rise in interventional treatments has become necessary due to the increase in arterial blockages that result from sedentary lifestyles, diabetes, obesity, and hypertension. DEBs provide a minimally invasive method for patients, in which antiproliferative drugs are directly delivered to the vessel wall, thereby reducing restenosis while maintaining vessel integrity. The demand for drug-eluting balloons in hospitals and catheterization laboratories is increasing with the worldwide aging population that is more vulnerable to atherosclerosis. Clinical trials demonstrating lower rates of recurrence and improved patient outcomes support their use. Moreover, the development of healthcare infrastructure and the increasing awareness of minimally invasive procedures are, thus, contributing to the market growth.

Advancements in Drug-Coating Technologies and Material Innovations are Accelerating Drug-Eluting Balloon Market Expansion.

Technological innovations in drug-coating mechanisms and balloon materials are the main factors that are hugely advancing the DEB market. New generation coatings with biocompatible polymers and optimized antiproliferative agents, such as paclitaxel and sirolimus, guarantee accurate drug delivery, better tissue absorption, and lower risks of inflammation or delayed healing. The biodegradable balloons and hybrid therapies combining DEBs with stents, etc., are some of the innovations that enhance the treatment versatility for the complex lesions. The use of AI, imaging, and computational modeling for the optimization of balloon designs and for the controlled drug-release profiles thus increases procedural efficiency and clinical confidence are increased. Continuous R&D investments and regulatory support all over the world are speeding up the commercialization of advanced DEB products that, in turn, are driving the broader adoption of DEBs in global healthcare settings.

Market Restraints and Challenges:

The Drug-Eluting Balloon (DEB) market is heavily restrained and challenged, that it cannot be fully adopted to its full extent. One of the reasons is the expensive DEB procedure combined with insufficient reimbursement policies, especially in developing regions, which makes it difficult for healthcare providers and patients to have access to the technology despite its clinical advantages. Besides that, technical difficulties, for example, ensuring drug transfer efficiency, coating durability, and effective drug delivery in atherosclerosis-stenosed vessels, are still the issues that manufacturers face. On the regulatory side, regulators require long and rigorous approval processes, and there is a lack of standardized clinical protocols, which causes delays in product commercialization and restricts the speed of innovation. Together, financial, technical, and regulatory barriers are slowing down the global adoption of DEB technology; thus, it is still challenging to get clinical acceptance in the long term, and there will be limited growth of the market.

Market Opportunities:

The Drug-Eluting Balloon (DEB) market is full of potential for growth due to changing healthcare trends and innovations in technology. Essentially, the expansion of DEB use in ambulatory surgery centers (ASCs) is a big opportunity where minimally invasive, same-day procedures are most likely to be chosen because they are cheaper and the hospital stays are shorter. Favorable reimbursement policies and the shift toward outpatient care are the two main factors that are facilitating this adoption; thus, ASCs are positioned as a major channel for market growth. Concurrently, innovations in drug formulations and coating technologies are opening new horizons for breakthroughs. The increasing use of sirolimus-based DEBs, which is being supported by the safety data for the long term and the improvement in coating by the TransPac method, is the two things that enhance the effectiveness and the safety of these devices; thus, their clinical appeal is getting higher. These trends, in fact, highlight the potential of the DEB market to grow further through the strategic deployment in the outpatient sector and continuous evolution in technology.

DRUG-ELUTING BALLOON MARKET REPORT COVERAGE:

Drug-Eluting Balloon Market Segmentation:

Drug-Eluting Balloon Market Segmentation By Type:

• Coronary Drug-Eluting Balloons (DEBs)
• Peripheral Drug-Eluting Balloons (DEBs)
• Other Products (Renal/Urology)

Coronary Drug-Eluting Balloons (DEBs) are the leading products of the market, representing the major share in the Drug-Eluting Balloon segment. The balloons are mainly employed in the treatment of diseases of the coronary arteries, offering the delivery of drugs locally in order to avoid restenosis after angioplasty. Their extensive use is a result of the large number of cardiovascular diseases worldwide and the trend of patients choosing less invasive methods instead of the conventional stenting. The segment is perpetually renovated with the technological improvements in drug coating, balloon design, and procedural efficiency; thus, coronary DEBs are the core of the market.

Peripheral Drug-Eluting Balloons (DEBs) are the most rapidly expanding subsegment of the market. As a result of the growing number of patients with peripheral artery diseases and the popularity of minimally invasive interventions, these balloons used for the treatment of peripheral arterial diseases in limbs are becoming a widely used method. The segment's expansion is fueled by the extension of the uses of the devices to areas other than the coronary arteries, the presence of good reimbursement policies, and the invention of the next-generation peripheral DEBs that provide better drug delivery and improved clinical outcomes.

Drug-Eluting Balloon Market Segmentation By Application:

• Coronary Intervention
• Peripheral Intervention
• Renal/Urology

Coronary Intervention is the major contributor to the Drug-Eluting Balloon market as it continues to be the most viable option for the treatment of coronary artery diseases. The segment enjoys a surge in the number of cardiovascular disorder cases, the widespread use of minimally invasive procedures, and the innovations in DEB technology that lower the incidence of restenosis. The demand for DEBs is on the rise in hospitals and cardiac centers as they are the most efficient means of drug delivery and offer better patient outcomes. The expansion of the segment is a result of the extensive clinical studies that prove the effectiveness of DEB in coronary arteries and the increased global volume of cardiac interventions.

Peripheral intervention represents the most rapidly expanding subsegment in the Drug-Eluting Balloon market. The use of the product in peripheral arterial diseases, especially in the lower limbs, is the main reason for the increasing demand. New developments in balloon coatings and drug formulations have largely contributed to the success of the procedure, making the periphery interventions safer and more effective. Moreover, the growing occurrence of diabetes and obesity-related vascular complications is a major factor behind the increased use of DEBs in peripheral arteries. The quick expansion of this segment is indicative of the trend toward minimally invasive treatments in non-coronary areas, mainly in developing countries.

Drug-Eluting Balloon Market Segmentation: Regional Analysis:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East & Africa

The Drug-Eluting Balloon market is mainly influenced by North America, with its cutting-edge healthcare infrastructure, the high rate of minimally invasive procedures, and the general awareness of cardiovascular diseases. The region's leadership has been solidified by the presence of the key market players, the advantageous reimbursement policies, and the technological advancements in interventional cardiology. Hospitals and specialized cardiac centers are upgrading their facilities with DEBs to enhance patient outcomes and to lessen the incidence of post-procedure complications. This supremacy is backed up by intensive clinical research efforts and the early uptake of next-generation DEB technologies.

Asia-Pacific is the most rapidly expanding region of the DCB market, mainly due to factors such as increasing prevalence of cardiovascular diseases, development of the healthcare sector, and rising middle-class incomes. The knowledge of innovative, less invasive surgical methods has made the use of DEBs widely accepted in such emerging nations as China, India, and Japan. The momentum of the market penetration is being boosted by government programs that support sophisticated cardiovascular care, along with the expanding hospital networks and rising health insurance coverage. The rapid urbanization and a huge pool of patients are also among the major factors contributing to this region's impressive growth curve, which makes it a pivotal area of opportunities for market players.

Drug-Eluting Balloon Market COVID-19 Impact Analysis:

The COVID-19 pandemic disrupted the Drug-Eluting Balloon (DEB) market significantly, changing demand patterns and operational dynamics worldwide. Elective and non-emergency cardiovascular procedures were generally postponed during the first few waves, so the use of DEB temporarily decreased. Hospitals and healthcare providers that had to deal with COVID-19 the most were the ones deciding which resources to use; hence, interventional cardiologists specialized in routine cardiovascular procedures will be the ones less utilized. Disruptions in the supply chain affected the situation further, as the delivery of both raw materials and finished DEB products was delayed in regions that rely heavily on cross-border logistics. With all these barriers, the pandemic acted as an accelerator for minimally invasive therapies as healthcare systems embraced those therapies that guarantee shorter hospital stays and less exposure to infection. Furthermore, the increased awareness of cardiovascular health risks in COVID-19 patients made radical interventions like DEB more welcomed in the post-pandemic recovery. The telemedicine and remote monitoring of chronic patients also allowed pre- and post-care for DEB patients, crossing the continuity of the treatment chain during lockdown limitations. The pandemic put the brakes on growth initially; however, it also made the strategic value of DEBs in future smart and stable healthcare systems more visible, which, therefore, led to a trickle-down effect of more robust adoption when healthcare systems stabilized and elective procedures resumed.

Latest Market News:
 

• In February 2025, Teleflex announced its acquisition of BIOTRONIK's vascular intervention business for approximately €760 million. This strategic move expanded Teleflex's portfolio to include a broad range of vascular intervention devices, such as drug-coated balloons, drug-eluting stents, and balloon catheters. The acquisition aims to strengthen Teleflex's position in the interventional cardiology and peripheral vascular markets.
   
• In December 2023, OrbusNeich Medical Group Holdings completed the acquisition of eucatech AG, a company specializing in the development and manufacture of drug-coated balloon technologies. This acquisition is part of OrbusNeich's strategy to enhance its product portfolio and expand its presence in the global drug-coated balloon market.
   

Latest Trends and Developments:

The Drug-Eluting Balloon (DEB) industry is on the move in a major way, due to changes in drug formulations and coating technologies. Among these changes, the increased use of sirolimus-coated and bioresorbable balloons that enhance safety and long-term efficacy stands out. The rising clinical applications in coronary, peripheral, and renal interventions are the main factors behind the increasing demand for DEBs. At the same time, the preference for minimally invasive procedures and same-day discharges in ambulatory surgery centers is changing the way treatments are carried out. While North America is still the region that is most advanced in terms of healthcare infrastructure and, thus, is the leader in device adoption, the Asia-Pacific region is turning into the market with the highest growth rate. This growth is mainly driven by a rising prevalence of cardiovascular diseases and better healthcare access. The regulatory approvals, for instance, the clearance by the U.S. FDA of Boston Scientific’s Agent balloon for coronary in-stent restenosis, are the factors that demonstrate the trend of DEBs being more and more accepted as a viable alternative to the conventional stenting method. In general, the market is marked by innovations, broader clinical use, and the expansion to new regions; thus, it is positioned for continuous growth and further advancements in vascular interventions.

Key Players in the Market:

1. Medtronic plc
2. Boston Scientific Corporation
3. Becton, Dickinson and Company (BD)
4. Terumo Corporation
5. Koninklijke Philips N.V.
6. B. Braun Melsungen AG
7. Biotronik SE & Co. KG
8. Cook Medical
9. Concept Medical Inc.

10. Abbott Laboratories